Kala Bio Inc (KALA)
6.82
+0.04
(+0.60%)
USD |
NASDAQ |
Nov 05, 11:46
Kala Bio Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2022 | -44.05 |
| June 30, 2022 | -2.529 |
| March 31, 2022 | -15.02 |
| December 31, 2021 | 4.697 |
| September 30, 2021 | 1.277 |
| June 30, 2021 | 0.9262 |
| March 31, 2021 | 0.6605 |
| December 31, 2020 | 0.7225 |
| Date | Value |
|---|---|
| September 30, 2020 | 0.6787 |
| June 30, 2020 | 0.556 |
| March 31, 2020 | 0.5048 |
| December 31, 2019 | 2.397 |
| September 30, 2019 | 1.648 |
| June 30, 2019 | 1.158 |
| March 31, 2019 | 0.8554 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-44.05
Minimum
Sep 2022
4.697
Maximum
Dec 2021
-4.098
Average
0.6696
Median
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.4322 |
| IGC Pharma Inc | 0.0173 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Protalix BioTherapeutics Inc | 0.7145 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 61.61M |
| Total Liabilities (Quarterly) | 47.89M |
| Shareholders Equity (Quarterly) | 13.72M |